Latest Argininosuccinate synthetase Stories
Revolutionary dietary supplement from Neogenis® Labs supported struggling teen’s circulation and helped his body normalize blood pressure. Austin, TX
In the spring of 2010, Baylor College of Medicine's Dr. Brendan Lee received a desperate email from the mother of one of his patients.
WEINHEIM, Germany, May 17, 2011 /PRNewswire/ -- International biotechnology firm Cytonet, which is investigating a liver cell infusion of donated human liver cells for the treatment of urea cycle disorders (UCD) in young children, announced it has been granted orphan drug designation by the U.S.
Childrenâ€™s Memorial Hospital in Chicago is one of only 12 sites across the United States enrolling patients in a national clinical research trial which, for the first time is the United States, is using an investigational liver cell infusion to treat urea cycle disorders (UCDs) in children. UCDs are congenital and often life-threatening disorders of ammonia metabolism in the liver.
WEINHEIM, Germany, April 14, 2011 /PRNewswire/ -- International biotechnology firm Cytonet recently launched the first ever clinical trial in the United States using an investigational liver cell infusion to treat urea cycle disorders (UCD) in children.
SAN DIEGO, April 8, 2011 /PRNewswire/ -- Polaris Group (Polaris) announced today that data from preclinical studies suggest ADI-PEG 20, the Company's pegylated arginine deiminase therapeutic, may be effective in treating acute myeloid leukemia (AML), glioblastoma multiforme (GBM) and bladder cancer.
NEW YORK and SAN DIEGO, Feb. 14, 2011 /PRNewswire/ -- Polaris Group (Polaris) and The Ludwig Institute for Cancer Research (LICR) today announced the enrollment of the first patient in a Phase 2 clinical trial evaluating ADI-PEG 20 in the treatment of small cell lung cancer (SCLC).
- A transitional zone between two communities containing the characteristic species of each.